drugset
drugset / Trial / NCT04971746

Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects

NCT04971746 ↗

Phase 1 Completed 58 enrolled Lakefront Biotherapeutics NV
Non-randomizedCrossoverOpen-labelBasic science

Summary

The main aim of this study is to investigate the possible effect of GLPG4716 on the pharmacokinetics (PK) of pirfenidone and nintedanib. Further aims are to investigate safety and tolerability of GLPG4716 alone or administered simultaneously with pirfenidone or nintedanib.

Timeline

Start
2021-07-19
Primary completion
2022-05-09
Completion
2022-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject 5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYLMORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINE Small molecule — —
Subject Nintedanib Small molecule — Oral
Subject Pirfenidone Small molecule — Oral

Indications

No indication recorded.